2022-03-07 - Cancer Synoptic Reporting Project Group Meeting

1

Treatment effect

Scott Campbell

Continue discussion:

What are we measuring when assessing "treatment effect"?  

Is this a histologic change?  Viability of tumor cells?

1. Primary site

2. Lymph node

Note: SSA wonders about property in this model

1. Primary site

   Open

   

   
   
   
   

2. Lymph node

Open

Will review model.  This observable pertains to the process of regression/change in the neoplasm after antineoplastic therapy.  So, observable could be modeled as presence of process changes.

Still a discussion.  What is being measured?  (Degree of presence of tumor). Can this be reproduced...base question is tumor there or not s/p therapy...tumor gone is best...everything else is questionable for the patient

2

Patterns

Scott Campbell

1. How to handle patterns within histologies

   1. Lung (Lepidic, acinar)

   2. DCIS

   3. Bladder (differentiation)

We can use the morphologic descriptors...maybe...TBD

3

Lymph nodes

Scott Campbell

Stefan Dubois (Unlicensed)

1. Discuss approach to lymph node body structures and differences in naming/locations (example AJCC esophageal cancer vs. JES esophageal cancer)

2. Management of observables for lymph node involvement.  Example: 

4

AJCC update?

Jim Case

Any updates that can be shared?

Jim Case meeting with AJCC on Wednesday 26-Jan to continue/finalize contract issues